Promising Outcomes with Pola-R-CHP in Newly Diagnosed Diffuse Large B Cell Lymphoma with Aberrant p53 Expression
医脉通 2024.12.25
ASH Live Review
11条内容
Promising Outcomes with Pola-R-CHP in Newly Diagnosed Diffuse Large B Cell Lymphoma with Aberrant p53 Expression
摘要 ：https://ash.confex.com/ash/2024/webprogram/Paper198122.html
1
Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R2) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study
2
Guidance 05: A Prospective, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Genotype-Guided Targeted Agents in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide,
3
The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma
4
Obinutuzumab is a Promising Alternative for the Treatment of Relapsed or Refractory Autoimmune Hematological Disorders
5
侵袭性淋巴瘤专场
